Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Launches Takeover Bid For Australian Biotech Arana

This article was originally published in The Pink Sheet Daily

Executive Summary

Arana’s lead compound ART621 is a new-generation TNF alpha blocker in Phase II trials for rheumatoid arthritis and psoriasis.
Advertisement

Related Content

Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
Mystery Shopper Arana Stops Trading On ASX Until “Take Over” Announced
Australian Biotech Faces Perfect Storm
Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says
Antibody Technology Fuels Deals For Arana In Australia, Japan, Korea: PharmAsia News Spotlight

Topics

Advertisement
UsernamePublicRestriction

Register

PS069059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel